Originally appeared in Investor Place written by Josh Enomoto
Whenever you’re dealing with pot stocks, it’s difficult to filter hype from reality. While I broadly consider the sector a paradigm-shattering opportunity, whenever money is involved, hucksters quickly follow. That’s why I appreciate what Marimed(OTCMKTS:MRMD) has to offer.
Primarily, I dig MRMD stock for the underlying company’s business model. Any new venture requires expert advice, whether it be legal, operational, or managerial. This is especially true for cannabis-related businesses in the U.S. While the midterm elections could make marijuana legal in a total of 11 states and the District of Columbia, the federal government still considers the plant a Schedule I drug.
Marimed helps cannabis firms navigate multiple potential pitfalls, making MRMD stock a utilitarian investment. More importantly, the company’s leadership and advisory team has professionals in the legal, financial, and law-enforcement sectors. That gives on-the-fence investors added confidence to take a shot.
Most importantly, the markets believe in Marimed. While so many marijuana stocks faltered in October, MRMD stock actually gained double digits! This is a name you must keep a close eye on post midterms.